title: [Neuronal death in the neocortex of drug resistant temporal lobe epilepsy patients].
abstract: Introduction. Participation of apoptotic death mechanisms in drug resistant temporal lobe epilepsy (DRTLE) is currently under great debate. We have investigated if there is neuronal loss and the immunodetection to different markers in neocortical tissue death in eigth patients with DRTLE. The neocortexes of five patients deceased due to non-neurological causes, paired in age and gender were evaluated as control tissue. Methods. The evaluation of neuronal loss was made by means of a stereological study and with immunohistochemical techniques with the synaptophysin marker. Immunopositivity to different apoptotic markers (annexin V, caspase 3 and 8, bcl-2 and p53) and detection of deoxyribonucleic acid (DNA) fragmentation (TUNEL) were analyzed and double labeling with synaptophysin was performed in every case. The results were evaluated with confocal microscope and analyzed with the Zeiss LSM 5 Image Browser Program, 2.80.1113 (Germany). Results. A statistically significant decrease in the total number of cells (p < 0.05) and the synaptophysin cells+ (p<0.01) in the neocortex (layer IV) of the patients with DRTLE when compared with the control tissue was found. No significant differences were found in the apoptotic markers bcl-2, p53, caspase 3 and 8 for any of the neocortex layers while there was a statistically significant increase in the number of TUNEL cells+ (p<0.05) and annexin V+ (p<0.05) in the neocortical layer IV of the patients. Conclusions. This group of evidence speaks in favor of the existence of an effect on the neuronal number in the neocortex layer IV that may be associated with noncaspase dependent apoptotic death process, without being able to rule out death by necrosis. Key words: Drug resistant temporal lobe epilepsy. Apoptosis. Necrosis. Neuronal loss. Neurología 2008;23(9):555-565.
authors.affiliation: Centro Internacional de Restauración Neurológica (CIREN), Hospital Siglo XXI, IMSS, México. lourdes.lorigados@infomed.sld.cu
authors.forename: L
authors.initials: L
authors.lastname: Lorigados Pedre
authors.forename: S
authors.initials: S
authors.lastname: Orozco Suárez
authors.forename: L
authors.initials: L
authors.lastname: Morales Chacón
authors.forename: I
authors.initials: I
authors.lastname: García Maeso
authors.forename: B
authors.initials: B
authors.lastname: Estupiñán Diaz
authors.forename: J E
authors.initials: JE
authors.lastname: Bender del Busto
authors.forename: N
authors.initials: N
authors.lastname: Pavón Fuentes
authors.forename: B
authors.initials: B
authors.lastname: Paula Piñero
authors.forename: L
authors.initials: L
authors.lastname: Rocha Arrieta
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D016923:Cell Death; D004351:Drug Resistance; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D020287:In Situ Nick-End Labeling; D008297:Male; D008875:Middle Aged; D019579:Neocortex / Q000473:pathology* / Q000503:physiopathology; D009474:Neurons / Q000473:pathology*
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers